Loading
RRM2B (Ribonucleoside-diphosphate reductase subunit M2 B) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 5 more.
Plays a pivotal role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free radical centre required for catalysis.
Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.93, animal model 0.50, genetic association 0.07, clinical 0.99).
In plain words · RRM2B (Ribonucleoside-diphosphate reductase subunit M2 B) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 5 more.
RRM2B (Ribonucleoside-diphosphate reductase subunit M2 B) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 5 more.
Plays a pivotal role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for DNA repair in cells arrested at G1 or G2.
No product in this corpus aims at RRM2B yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA RRM2B: RNA low tissue specificity; high antibody staining in 19 normal tissues; highest cancer staining thyroid cancer (2 of 4 high). Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Lymphoma, Breast cancer (all types), Lung cancer (all types), Ovarian cancer, Myeloid neoplasms); Open Targets associates it with 11 specific cancer types at or above 0.5 (non-small cell lung carcinoma, B-cell chronic lymphocytic leukemia, exocrine pancreatic carcinoma, melanoma, ovarian carcinoma, breast cancer and more). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas RRM2B tissue; Open Targets ENSG00000048392 associations
First described 2000. Earliest sequence paper UniProt cites for the protein: Tanaka et al, Nature, 2000, "A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage". Source.
Sources: HGNC HGNC:17296 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q7LG56 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000048392 (association with cancer (MONDO_0004992) 0.64; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.60, ovarian cancer 0.58, melanoma 0.57, acute lymphoblastic leukaemia 0.60, B-cell chronic lymphocytic leukaemia 0.59, non-Hodgkin lymphoma 0.61 (GraphQL API, CC0))
Plays a pivotal role in cell survival by repairing damaged DNA in a p53/TP53-dependent manner. Supplies deoxyribonucleotides for DNA repair in cells arrested at G1 or G2. Contains an iron-tyrosyl free radical centre required for catalysis. Forms an active ribonucleotide reductase (RNR) complex with RRM1 which is expressed both in resting and proliferating cells in response to DNA damage. Location: Cytoplasm; Nucleus (UniProt). Locus 8q22.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Breast, Cervix, Duodenum, Gallbladder, Hippocampus, Kidney, Oral mucosa, Pancreas.
Medium only: cervical cancer, ovarian cancer, skin cancer.
HPA RRM2B tissue · HPA RRM2B pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"RRM2B" OR ABSTRACT:"RRM2B" OR TITLE:"ribonucleotide reductase regulatory TP53 inducible subunit M2B" OR ABSTRACT:"ribonucleotide reductase regulatory TP53 inducible subunit M2B" OR TITLE:"Ribonucleoside-diphosphate reductase subunit M2 B" OR ABSTRACT:"Ribonucleoside-diphosphate reductase subunit M2 B" OR TITLE:"p53R2" OR ABSTRACT:"p53R2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RRM2B, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.